Navigation Links
OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
Date:5/28/2008

HONG KONG, May 28 /PRNewswire/ -- OrbusNeich today announced that it has received approval from the Department of Health to market the Genous Bio-engineered R stent in Taiwan.

The Genous stent is coated with an antibody to capture a patient's endothelial progenitor cells (EPCs) circulating in the bloodstream. When attracted to the inner surface of the Genous stent, EPCs have been shown to quickly form a healthy layer of endothelium that minimizes stent restenosis and provides protection against stent thrombosis.

"We are pleased to be able to offer the Genous stent to interventional cardiologists in Taiwan," said Teddy Chien, OrbusNeich's chairman. "The introduction of our pro-healing stent to the Taiwanese market is an important step for our company as we expand our presence in the Asia-Pacific region. Based on our interaction with Taiwanese physicians, we expect strong Genous sales from the outset because of the demand for safe alternatives to drug-eluting stents."

An estimated 20,000 coronary angioplasty procedures will be performed in Taiwan in 2008, 60% of which are expected to involve the use of drug eluting or coated stents.

"We are pleased to have Genous stents become available in Taiwan," said Jui-Sung Hung, M.D., FACC, FAHA, founding President of the Taiwan Society of Cardiovascular Interventions. "Preliminary studies have shown that the use of Genous stents is as safe and effective as TAXUS DES, and more importantly, that the stent thrombosis rate at 12 months is lower with the Genous stent despite one month of dual antiplatelet therapy. Although results of large-scale, randomized control trials are awaited to make more definitive conclusions, I believe Genous will be a good treatment option for patients who cannot undergo long-term dual antiplatelet therapy or patients who have increased risk of thrombotic events."

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

As a global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
2. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
3. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
4. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
5. Cornell receives federal grants to create fabrics to render toxic chemicals harmless
6. Einstein-Montefiore Center for AIDS Research receives $8.5M award from NIH
7. Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling
8. TriWest Receives National Awards for Innovative Video Communications to Military Community
9. A.S.V., Inc. Receives Safety and Health Award
10. Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence
11. LMI Receives CDC/ATSDR Public Health Improvement Award for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... unique opportunity that helps high school girls succeed in STEM programs as well ... Horizon Goodwill will host over 20 high school girls at their corporate headquarters ...
(Date:7/24/2017)... ... , ... Every year, thousands of dedicated Higher Education and K12 professionals flock ... coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to take ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured ...
(Date:7/24/2017)... ... July 24, 2017 , ... A CDC study shows that, although people are taking more ... 18 to 29), had at least one case of sunburn within the past year. It’s ... people to ignore the issue. However, only recently have people become conscientious of the risks ...
(Date:7/24/2017)... ... , ... Sharon Kleyne, host of the nationally syndicated The Sharon Kleyne Hour ... Tears® EyeMist® recently talked on the air about an alarming Post magazine article of ... Zidor Aldama described the situation in which Chinese children are under pressure to perform ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/21/2017)... -- Did you know that PhRMA member companies invested $65.5 billion ... on brand medicines, generics and the supply chain account for 14 ... half of this (7 percent)? Or that the United ... capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry ...
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
Breaking Medicine Technology: